Aytu Biopharma (AYTU) Stock News

Aytu BioPharma has expanded and extended its lending agreement with Eclipse Business Capital, strengthening its financial position ahead of EXXUA's commercial launch. The term loan maturity has been extended to June 2029, with the principal balance increased to $13.0 million from $11.1 million. The revolving credit facility has been expanded by $1.5 million. This follows Aytu's recent exclusive agreement to commercialize EXXUA, a first-in-class antidepressant for major depressive disorder, in the U.S. market worth over $22 billion. EXXUA has shown promising results in clinical trials with over 5,000 patients, demonstrating significant improvement in depression symptoms with sexual side effects comparable to placebo. The company recently closed a $16.6 million public offering and plans to launch EXXUA in Q4 2025.

Aytu BioPharma has closed an upsized at-the-market public offering, raising $16.6 million in gross proceeds through the sale of common stock and prefunded warrants. The offering was led by healthcare-focused institutional investors including Nantahala Capital Management and Stonepine Capital Management. The funds will support the commercialization of EXXUA, a first-in-class FDA-approved antidepressant for Major Depressive Disorder (MDD). EXXUA, a selective serotonin 5HT1a receptor agonist, has shown significant improvement in depression symptoms across 5,000+ patient trials with sexual side effects comparable to placebo. Unlike SSRIs, EXXUA has no reuptake inhibition activity and shows no significant adverse effects on weight, blood pressure, heart rate, or liver function. The company plans to launch EXXUA in Q4 2025, targeting the $22 billion US prescription MDD market.

Aytu BioPharma (NASDAQ:AYTU) has announced the pricing of an upsized public offering of 9.6 million shares of common stock at $1.50 per share, with potential for an additional 1.44 million shares through a 30-day underwriter option. The offering, led by Nantahala Capital Management and Stonepine Capital Management, is expected to raise approximately $14.4 million in gross proceeds. The company plans to use the funds for general corporate purposes, working capital, and to secure exclusive commercialization rights for EXXUA, an FDA-approved treatment for major depressive disorder. Lake Street Capital Markets is acting as sole book runner, with Maxim Group as lead manager. The offering is expected to close around June 9, 2025.

Aytu BioPharma (NASDAQ:AYTU) has secured exclusive rights to commercialize EXXUA (gepirone), a first-in-class antidepressant, in the United States. EXXUA is a novel selective serotonin 5HT1a receptor agonist FDA-approved for treating Major Depressive Disorder (MDD) in adults. The drug has shown significant efficacy in clinical trials involving over 5,000 patients and notably demonstrates sexual side effects comparable to placebo. EXXUA will compete in the $22 billion US prescription MDD market, with launch expected in Q4 2025. The deal is financed by healthcare-focused investors including Nantahala Capital Management and Stonepine Capital Management. Unlike SSRIs, EXXUA has no reuptake inhibition activity and shows no significant adverse effects on weight, blood pressure, heart rate, or liver function. The agreement includes an upfront payment, fixed payment at one-year post-launch, royalties on net revenue, and performance-based milestone payments.

Aytu BioPharma (NASDAQ:AYTU) reported strong financial results for Q3 FY2025. The company achieved total net revenue of $18.5 million, up 32% year-over-year, driven by growth in both ADHD and Pediatric portfolios. The ADHD Portfolio revenue increased 25% to $15.4 million, while the Pediatric Portfolio saw a 77% increase to $3.1 million. The company reported net income of $4.0 million ($0.65 basic and $0.21 diluted EPS), compared to a net loss in Q3 FY2024. Adjusted EBITDA improved to $3.9 million from $0.9 million year-over-year. Cash position stood at $18.2 million, with the company reducing long-term debt by $2.5 million during the quarter. Gross profit was $12.8 million (69% margin), slightly down from 74% in the previous year due to temporary manufacturing transition costs.

Aytu BioPharma (NASDAQ:AYTU) has scheduled its fiscal 2025 third quarter operational and financial results announcement for May 14, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time, featuring a results review and Q&A session.

Participants can join via phone using the numbers (888) 506-0062 (US) or +1 (973) 528-0011 (international) with access code 314386. The webcast will be available live and archived at the company's investor relations website. A replay will be accessible until May 28, 2025.

Aytu BioPharma (NASDAQ:AYTU) has announced its participation in the upcoming Planet MicroCap Showcase: VEGAS 2025. The presentation is scheduled for Wednesday, April 23, 2025, at 1:30 PM Pacific time (4:30 PM Eastern) at Track 3 - Chablis in the Paris Hotel & Casino, Las Vegas.

CEO Josh Disbrow will lead the presentation and conduct a Q&A session. The event will be available via webcast, and the company will also hold one-on-one meetings with interested parties on April 24, 2025, at the conference venue. Investors interested in scheduling 1x1 meetings can coordinate through their Planet MicroCap representative or contact the company's investor relations team.

Aytu BioPharma (AYTU) reported fiscal Q2 2025 results with net income of $0.8 million and Adjusted EBITDA of $1.3 million. The company's Pediatric Portfolio showed strong performance with an 86% sequential increase in net revenue to $2.4 million, while the ADHD Portfolio revenue increased 16% sequentially to $13.8 million (adjusted for one-time effects).

Total net revenue was $16.2 million, with both portfolios showing the first quarterly sequential prescription growth since late-2022. The company maintained a strong cash position of $20.4 million as of December 31, 2024. Gross profit was $10.8 million (66% of net revenue), down from 78% in the previous year due to temporary manufacturing transition costs.

The company completed its strategic restructuring, including the divestiture of its Consumer Health business and closure of its Texas manufacturing facility, expecting at least $2.0 million in additional annual cost savings.

Aytu BioPharma (NASDAQ:AYTU) has announced it will release its fiscal 2025 second quarter operational and financial results on February 12, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time, featuring a results review and Q&A session.

Investors can join the conference call by dialing (888) 506-0062 (US) or +1 (973) 528-0011 (international) using access code 583044. The webcast will be available live and archived at the company's investor relations website. A replay will be accessible until February 26, 2025.